{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-073432","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.631389+00:00","generated_at":"2026-06-07T06:16:28.295212+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Lyra Therapeutics subleases ~23,704 sq ft lab/office in Waltham, MA","bullets":["Sublease with RVAC Medicines for 23,704 sq ft at 880 Winter Street, Waltham, MA.","Term expected to start Jan 1, 2024; expires Nov 30, 2032.","Monthly base rent $150,125.33 (~$1.8M annual); 3% annual escalator; first two months rent-free.","Requires $450,375.99 letter of credit as security deposit; also pays share of operating expenses, utilities, taxes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-073432","json":"https://secwatch.observer/filing/0000950170-23-073432.json","markdown":"https://secwatch.observer/filing/0000950170-23-073432.md","text":"https://secwatch.observer/filing/0000950170-23-073432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023073432/0000950170-23-073432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023073432/lyra-20231221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:16:28.295212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee6d3be6d7867dcccbeecfb588d849376f895cd4","claim":"Lyra Therapeutics, Inc. entered into Sublease with RVAC Medicines (US), Inc. valued at $1,801,503.96 (effective 2023-12-21).","evidence_excerpt":"On December 21, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a sublease agreement (the “Sublease”) with RVAC Medicines (US), Inc., a Delaware corporation (the “Sublessor”), for approximately 23,704 square feet of laboratory and office space at 880 Winter Street in Waltham, Massachusetts (the “Premises”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023073432/0000950170-23-073432-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"RVAC Medicines (US), Inc."},{"label":"Value","value":"$1,801,503.96"},{"label":"Effective","value":"2023-12-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}